Back to Search
ELIJAH DOUGLASS, M.D.
M.D.
Hospitalist Physician
NPI: 1669866570IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hospitalist PhysicianPrimary
Hospitalist
Code: 208M00000X
293672(NY)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
293672(NY)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
NEW YORK MEDICAL COLLEGE
Class of 2015
Research & Publications (20)
Analysis of the temporal requirement for eda in hair and sweat gland development.
PMID 18923450·J Invest Dermatol·2009
7-preclinical
Effect of electrode roughness on the capacitive behavior of self-assembled monolayers.
PMID 18811215·Anal Chem·2008
8-other
Photocurrent generation in noncovalently assembled multilayered thin films.
PMID 18393555·Langmuir·2008
8-other
Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells.
PMID 17728319·Hum Mol Genet·2007
7-preclinical
Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21.
PMID 15981236·Genes Chromosomes Cancer·2005
8-other
Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma.
PMID 15641027·Cancer·2005
3-trial
Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity.
PMID 15623512·J Biol Chem·2005
7-preclinical
ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial.
PMID 15289725·Am J Clin Oncol·2004
3-trial
A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer.
PMID 14599861·Gynecol Oncol·2003
3-trial
Myeloperoxidase promotor polymorphism and risk of hepatoblastoma.
PMID 12800195·Int J Cancer·2003
4-observational
Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
PMID 12796367·Clin Cancer Res·2003
3-trial
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
PMID 12721264·J Clin Oncol·2003
3-trial
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
PMID 12684399·Clin Cancer Res·2003
3-trial
Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
PMID 12177104·J Clin Oncol·2002
3-trial
Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
PMID 12065555·J Clin Oncol·2002
3-trial
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
PMID 11230494·J Clin Oncol·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 525 E 68TH ST # 331
NEW YORK, NY 10065 - Phone
- (212) 746-4071
Quick Facts
- NPI
- 1669866570
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile